Evan David Seigerman
Stock Analyst at BMO Capital
(3.13)
# 1,250
Out of 5,006 analysts
48
Total ratings
43.18%
Success rate
4.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $228.90 | +4.85% | 8 | Sep 12, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $600 → $640 | $589.60 | +8.55% | 8 | Aug 4, 2025 | |
| REPL Replimune Group | Downgrades: Underperform | $27 → $2 | $4.62 | -56.71% | 4 | Jul 23, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $22.95 | +13.29% | 2 | Jun 12, 2025 | |
| MRUS Merus | Maintains: Outperform | $96 → $110 | $94.25 | +16.71% | 1 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $21.70 | +29.03% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $9.65 | +3.63% | 1 | May 5, 2025 | |
| NVO Novo Nordisk | Downgrades: Market Perform | $105 → $64 | $60.01 | +6.65% | 6 | Apr 17, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $88.81 | +8.10% | 4 | Feb 5, 2025 | |
| AMGN Amgen | Maintains: Outperform | $362 → $346 | $293.55 | +17.87% | 4 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $29.07 | +244.00% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $26.73 | +34.68% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.44 | -44.85% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $847.30 | -53.26% | 1 | Sep 6, 2022 |
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $228.90
Upside: +4.85%
Regeneron Pharmaceuticals
Aug 4, 2025
Maintains: Outperform
Price Target: $600 → $640
Current: $589.60
Upside: +8.55%
Replimune Group
Jul 23, 2025
Downgrades: Underperform
Price Target: $27 → $2
Current: $4.62
Upside: -56.71%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $22.95
Upside: +13.29%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $94.25
Upside: +16.71%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $21.70
Upside: +29.03%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $9.65
Upside: +3.63%
Novo Nordisk
Apr 17, 2025
Downgrades: Market Perform
Price Target: $105 → $64
Current: $60.01
Upside: +6.65%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $88.81
Upside: +8.10%
Amgen
Jan 29, 2025
Maintains: Outperform
Price Target: $362 → $346
Current: $293.55
Upside: +17.87%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $29.07
Upside: +244.00%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $26.73
Upside: +34.68%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.44
Upside: -44.85%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $847.30
Upside: -53.26%